Pinealon

Pinealon is the short-peptide bioregulator neuroscience researchers keep on the bench. A synthetic tripeptide (Glu-Asp-Arg) from the Khavinson peptide family developed at the St. Petersburg Institute of Bioregulation and Gerontology, it's studied for a striking proposed mechanism: penetrating the cell nucleus and interacting directly with DNA to modulate gene expression in neuronal tissue. Preclinical work has focused on its neuroprotective activity under hypoxia and oxidative stress, where models report reduced neuronal apoptosis, preserved learning and memory, and normalised antioxidant defence. Every 10 mg vial is research-grade material, third-party verified to 98.9% purity, and lyophilised for a clean, consistent reconstitution. Supplied strictly for research purposes only.

• Proposed nuclear penetration and direct DNA interaction modulating neuronal gene expression
• Reduces neuronal apoptosis under hypoxic and oxidative-stress conditions
• Preserves learning and memory parameters in stressed and aged animal models
• Normalises antioxidant enzyme activity in neural tissue research
• Protects against prenatal hyperhomocysteinemia-induced neuronal damage
• Influences circadian and behavioural regulation in preclinical studies
• Stable short-peptide bioregulator for epigenetic neuroprotection research

Research Administration

Subcutaneous injection, 2.5–5 mg daily for 10-day cycles in research protocols

For research purposes only. Not for human consumption.

• Store at −20°C in a dry, sealed environment
• Reconstitute with bacteriostatic water; use within 30 days at 4°C
• Avoid repeated freeze-thaw cycles
• Supplied for research purposes only — not for human or veterinary use